How would you manage a resectable satellite/in-transit melanoma recurrence that developed during adjuvant immunotherapy?

I'm not sure if there is one correct answer in this situation. Could consider intra-lesional TVEC therapy - particularly if the melanoma is BRAF wild type. If this is the case, can fold in an anti-PD-1 antibody in conjunction with intra-lesional TVEC. While this combination has failed in phase III s...